Skip to main content

Eye Diseases

5
Pipeline Programs
10
Companies
7
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Alcon
AlconFORT WORTH, TX
1 program
1
Next Generation Ophthalmic Irrigating SolutionPhase 31 trial
Active Trials
NCT00333203Completed369Est. Mar 2006
MSD
MSDIreland - Ballydine
1 program
1
Benzalkonium chloridePhase 11 trial
Active Trials
NCT00414739Unknown20
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
Benzalkonium chloridePhase 1
Opthea
OptheaAustralia - South Yarratoria
1 program
1
OPT-302Phase 11 trial
Active Trials
NCT02543229Completed51Est. Sep 2017
Active Biotech
Active BiotechSweden - Lund
1 program
1
laquinimodPhase 11 trial
Active Trials
NCT05187403Completed54Est. Jan 2023
Regeneron
RegeneronTARRYTOWN, NY
1 program
AfliberceptN/A
T-Therapeutics
T-TherapeuticsUK - Cambridge
1 program
DREAM OCTN/A1 trial
Active Trials
NCT05876689CompletedEst. Oct 2024
LENZ Therapeutics
LENZ TherapeuticsSOLANA BEACH, CA
1 program
Aceclidine + BrimonidinePHASE_11 trial
Active Trials
NCT05936489Completed30Est. Oct 2023
Glaukos
GlaukosALISO VIEJO, CA
1 program
iStentPHASE_41 trial
Active Trials
NCT00913029Completed192Est. Sep 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GlaukosiStent
AlconNext Generation Ophthalmic Irrigating Solution
LENZ TherapeuticsAceclidine + Brimonidine
Active Biotechlaquinimod
OptheaOPT-302
T-TherapeuticsDREAM OCT

Clinical Trials (7)

Total enrollment: 716 patients across 7 trials

NCT00913029GlaukosiStent

Evaluation of the iStent Versus Two Ocular Hypotensive Agents in Patients With Primary Open-angle Glaucoma (POAG)

Start: May 2009Est. completion: Sep 2012192 patients
Phase 4Completed
NCT00333203AlconNext Generation Ophthalmic Irrigating Solution

Next Generation Ophthalmic Irrigating Solution Posterior Segment Study

Start: Oct 2005Est. completion: Mar 2006369 patients
Phase 3Completed
NCT00414739MSDBenzalkonium chloride

Testing of Innocuousness of Benzalkonium Chloride on the Eye Concerning Possible Growth of Langerhans Cells

20 patients
Phase 1Unknown
NCT05936489LENZ TherapeuticsAceclidine + Brimonidine

Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia

Start: Jul 2023Est. completion: Oct 202330 patients
Phase 1Completed
NCT05187403Active Biotechlaquinimod

A Study of Laquinimod Eye-drops in Healthy Participants

Start: Dec 2021Est. completion: Jan 202354 patients
Phase 1Completed
NCT02543229OptheaOPT-302

Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD

Start: Jul 2015Est. completion: Sep 201751 patients
Phase 1Completed
NCT05876689T-TherapeuticsDREAM OCT

Swept Source OCT Imaging With the DREAM VG-OCT

Start: Oct 2023Est. completion: Oct 2024
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
10 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.